Differential enhancement of myocardial infarction was first recognized on computed tomographic (CT) images obtained with iodinated contrast material in the late 1970s. Gadolinium enhancement of myocardial infarction was initially reported for T1-weighted magnetic resonance (MR) imaging in 1984. The introduction of an inversion-recovery gradient-echo MR sequence for accentuation of the contrast between normal and necrotic myocardium was the impetus for widespread clinical use for demonstrating the extent of myocardial infarction. This sequence has been called delayed-enhancement MR and MR viability imaging. The physiologic basis for differential enhancement of myocardial necrosis is the greater distribution volume of injured myocardium compared with that of normal myocardium. It is now recognized that delayed enhancement occurs in both acute and chronic (scar) infarctions and in an array of other myocardial processes that cause myocardial necrosis, infiltration, or fibrosis. These include myocarditis, hypertrophic cardiomyopathy, amyloidosis, sarcoidosis, and other myocardial conditions. In several of these diseases, the presence and extent of delayed enhancement has prognostic implications. Future applications of delayed enhancement with development of MR imaging and CT techniques will be discussed.

Learning Objectives:
- Describe the mechanism of delayed contrast enhancement of the myocardium.
- Describe the expected signal intensity of the infarct core, the peripheral zone, microvascular obstruction, and the remote myocardium on delayed-enhancement images after myocardial infarction.
- List the most common delayed-enhancement patterns seen in nonischemic cardiomyopathies.
- List two prognostic applications of myocardial delayed-enhancement images.

Accreditation and Designation Statement
The RSNA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The RSNA designates this journal-based activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement
The ACCME requires that the RSNA, as an accredited provider of CME, obtain signed disclosure statements from the authors, editors, and reviewers for this activity. For this journal-based CME activity, author disclosures are listed at the end of this article. The editor and the reviewers indicated that they had no relevant relationships to disclose.
Delayed gadolinium-enhanced magnetic resonance (MR) imaging of ischemic and nonischemic myocardial disease has become an important application of cardiovascular MR imaging during the past decade. At many sites where cardiac MR is performed, myocardial tissue characterization is one of the most frequent clinical indications. In this review we will discuss the development of the imaging techniques, physiologic mechanisms, clinical applications for diagnosis and prognosis, and future perspectives on the use of delayed-enhancement imaging.

**Past: The Historical Perspective**

While the clinical use of differential contrast enhancement of abnormal myocardium has been a relatively recent advance, the concept of differential enhancement of myocardial infarction in both cardiac MR imaging and computed tomography (CT) goes back to studies published in the late 1970s. In the initial observations that established this concept, iodinated contrast media and CT of extirpated canine hearts with acute and chronic myocardial infarctions were used. Ex vivo CT of hearts with acute infarction demonstrated attenuation of the infarcted tissue that was dramatically higher than that of normal myocardium and that conformed to the site of increased uptake of technetium pyrophosphate (an infarct-avid radionuclide) and the regional deficit of the distribution of thallium 201 ($^{201}$Tl, a metabolic marker) (1,2) (Fig 1). The region of enhancement closely corresponded to the spatial extent of myocardial infarction as demarcated at histochemical morphometry (triphenyl tetrazolium chloride staining) (Fig 1). Iodine and technetium 99m ($^{99m}$Tc) pyrophosphate had the greatest concentration at the center of the infarct; a lower concentration at the periphery suggested a border zone of ischemic injury (Fig 2) (1). The enhancement of acute infarctions was later shown in the in situ beating heart by using a prototype electrocardiography (retrospective)-gated CT scanner in the early 1980s (3–5).

The concept of preferential and persistent enhancement of myocardial infarctions by gadolinium chelates was established by using MR imaging of canine hearts extirpated 5 minutes after administration of gadolinium-based contrast media (6,7). Shortly thereafter, the phenomenon of delayed contrast enhancement of acute myocardial infarctions was demonstrated in the in situ canine heart on electrocardiography-gated T1-weighted MR images (Fig 3) (8). By using electrocardiography-gated MR imaging of the intact animals, it was also shown that differential distribution of gadolinium-based contrast media could also be used to distinguish between reperfused and nonreperfused myocardial infarction (8); this method could help identify a no-reflow zone (microvascular obstruction). Early animal studies in which varying durations of ischemia were induced showed no delayed enhancement of reversibly injured myocardium (ischemia duration, <15 min) but delayed enhancement only of irreversibly injured myocardium (6–21).

The initial reports identifying differential gadolinium enhancement of myocardial infarctions in patients were published in the late 1980s (22,23).

deoos and co-workers (22) recognized different enhancement patterns in patients with occlusive infarction and those with reperfused infarction. Improvements in cardiac MR technology, along with the development of a sequence to greatly improve contrast between normal myocardium and infarction, stimulated widespread clinical application of gadolinium-enhanced MR imaging for demonstrating the presence, transmural extent, and size of myocardial infarctions. The MR sequence inversion-recovery gradient-echo imaging to null normal myocardial signal provided enormous contrast between the infarct and adjacent normal myocardium, which enabled ease and reliability of image interpretation (24).

**Present**

**Experimental Basis and Physiologic Mechanism of Delayed Gadolinium Enhancement of Myocardial Infarction**

Physiologic mechanism of delayed and persistent enhancement of damaged myocardium.— Currently used iodinated and gadolinium contrast media have a similar molecular size, which causes them to distribute rapidly in the extracellular space of the myocardium. These...
contrast media are excluded from normal myocardial cells. The differences in distribution volume for ischemically injured and normal myocardium were determined by Wendland et al (25) and Pereira et al (18,19). After administration of a gadolinium chelate, ratios of the difference in longitudinal relaxation rates for myocardium and blood at a time of equilibration of contrast medium distribution can be calculated by using repetitive echo-planar imaging in experimental animals (25). From these ratios, the fractional distribution volume of contrast material was estimated for normal and injured myocardium (Fig 4). The fractional distribution volume was about 0.2 in normal myocardium and greater than 0.9 in infarcted myocardium (Fig 25–27). These observations indicate that gadopentetate dimeglumine distributes in the extracellular space of normal myocardium but is excluded from the myocardial cell. On the other hand, the contrast medium distributes in the extra- and intracellular spaces after loss of myocardial membrane integrity in the infarcted region (Fig 5). In a series of experiments in rats with coronary occlusion of varying duration (20–60 minutes) followed by reperfusion, the ΔR1 ratios and fractional distribution volumes progressively increased with increasing severity of myocardial injury (26) (Fig 4). Moreover, the distribution volume of gadolinium-based contrast medium was lower at the periphery than at the core of the infarction, demonstrating the peripheral or perifocal or marginal zone of injury. In animals with occlusion of 20 minutes duration, the distribution volume increased to 32%, which was greater than the extracellular space of normal myocardium (19%). In these animals with no histochemical evidence of infarction, the modestly greater distribution volume presumably represented myocardial edema. The fractional distribution volume in the peripheral zone of animals with occlusion of 30–60 minutes duration, which caused myocardial infarction, was similar to the edematous myocardium of animals without histochemical evidence of infarction. These findings suggest that delayed gadolinium-enhanced MR can define a peripheral or perifocal zone of edema, as well as necrotic myocardium.

The mechanism of enhancement of myocardial scar in chronic infarction and other myocardial diseases is also likely due to expansion of the extracellular space compared with normal myocardium. Fibrosis (scar) has a larger extracellular space than does normal myocardium, which helps explain the regional enhancement of chronic healed infarctions. This is also likely the explanation for delayed enhancement in hypertrophic and other cardiomyopathies. Infiltrative myocardial diseases such as cardiac amyloidosis increase the extracellular space due to the infiltration. Some other myocardial pathologic conditions such as myocarditis may increase the distribution volume by means of a combination of edema and myocardial cell death.

Ischemic zone and peripheral zone.— By using multiple MR sequences with and without gadolinium enhancement, several zones can be defined in a region of ischemic myocardial injury: the ischemic zone, the infarction core of necrosis, the peripheral infarction zone, and the microvascular obstruction zone (Fig 6). The ischemic zone is defined as the ischemic area at risk for infarction after a coronary artery occlusion. T2-weighted black blood imaging with fat saturation can be used to detect the area at risk, which shows high signal intensity with this imaging sequence; this reflects myocardial edema as a result of the ischemic injury (28). Areas of myocardial infarct also show high signal intensity on these T2-weighted images but can be differentiated from the area at risk on the basis of the high signal intensity on delayed-enhancement images.

The delayed-enhancement areas consistent with nonviable myocardium are not homogeneous. Instead, delayed-enhancement areas may show a heterogeneous peripheral rim, called the peripheral zone, with lower signal intensity than that of the infarct core. The peripheral zone has been defined in several ways both in animal experiments (27) and in clinical studies (29,30). In animals, the peripheral zone was designated as signal intensity 2–4 standard deviations above that of normal remote myocardium at 5 minutes after gadolinium chelate injection at T1-weighted imaging. In clinical studies with patients, the peripheral zone was described in two ways: Yan and co-workers (29) defined a central, highly intense, myocardial infarct core as an area with signal intensity greater than 3 standard deviations above the intensity of the remote noninfarcted myocardium, whereas 2–3 standard deviations above normal was designated as the peripheral zone. Azevedo et al (30) defined the infarct core as an area with signal intensity above 50% of the maximal signal intensity measured in the delayed-enhancement myocardium. Any areas of signal intensity higher than the peak signal intensity of the remote myocardium but lower than 50% of the peak intensity as measured in the core zone was designated as peripheral zone.

As previously described in animal studies, the peripheral zone represents a region of nonviable myocardial cells interspersed with viable myocytes (15). The areas of lesser delayed enhancement corresponding to a peripheral zone are not only seen in the periphery of the infarct zone, but can also be detected in more central locations with areas of dense myocardial infarction (31–33).

Infarction size.— The zone of enhancement after gadolinium chelate administration has been found to have a close relationship to the size of the myocardial infarction demarcated at postmortem histochemical staining (histochemical morphometry) in animals (14,15,25–27,34). On T1-weighted images acquired several hours after coronary artery occlusion and reperfusion, the enhanced region demarcated by gadolinium enhancement was larger than, but proportional to, the infarction volume determined at histochemical morphometry. The difference in infarction volume as defined on gadolinium-enhanced images and true infarction size was considered to be due to a peripheral zone of potentially salvageable myocardium. In support of this notion, gadolinium-enhanced spin-echo MR imaging demonstrates a moderate peripheral zone on images acquired...
on the day of coronary occlusion, but this zone diminishes in size or disappears on images acquired 2–6 weeks after infarction. Presumably, the peripheral zone consists of edematous (reversibly injured) but not necrotic myocardium. In further support of this conclusion is the observation that MR images obtained 24 hours after reperfusion of acute myocardial infarction show a different size of the enhanced zone when gadopentetate dimeglumine is used than when the necrosis-specific contrast medium gadolinium-DTPA is used (14,15). The size of the gadolinium-DTPA–enhanced regions exactly matched the size of infarction defined at histochemical morphometry, while the area defined by gadopentetate dimeglumine was substantially larger. Other studies have also shown that the size of the gadolinium-DTPA–enhanced region exactly matched the infarction size from histochemical morphometry (20,34,35).

Using an inversion-recovery gradient-echo MR imaging (viability) sequence, Judd et al (12) found little difference between the enhanced region and infarction size at postmortem examination. Kim et al (13) reported an exact match between the enhanced zone on viability sequence images and infarction size at histochemical morphometry in dogs. In support of this notion that enhancement of any degree occurs only in necrotic myocardium, Kim et al (13) showed a “match” between 2-mm-thick tissue slices stained with triphenyl-tetrazolium chloride and postmortem MR images in hearts extirpated at the optimal delay after gadopentetate dimeglumine administration. On the basis of the results of these experiments, they concluded that in the setting of acute infarction with or without reperfusion, the spatial extent of infarction on inversion-recovery gradient-echo images is identical to the extent of myocardial necrosis. They attributed differences in size between the enhanced region and postmortem histochemical morphometry of infarction volume as previously reported to be due to partial volume errors.

Recognizing that partial volume error could potentially contribute to apparent differences between enhanced volume on in vivo MR images and true infarction volume at postmortem examination, Arheden et al (27) assessed tissue distribution of a radioactive co-

gener of gadolinium dimeglumine, 99mTc-labeled pentetate acid, in the presence of acute myocardial infarction. On autoradiographs of 10-μm-thick myocardial slices, three zones of radionuclide distribution were evident: a normal myocardial zone, a zone at the center with radioactivity 4 standard deviations higher than that of normal tissue, and a zone at the periphery of the infarct with radioactivity 2 standard deviations higher (Fig 7). These investigators concluded that a peripheral zone of delayed enhancement exists that cannot be attributed to partial volume effects on MR images of 3–5-mm thickness. It remains conjectural whether the inversion-recovery gradient-echo technique, which attempts to maximize contrast between infarcted and normal myocardium by nulling the signal of normal myocardium, can render the peripheral zone invisible.

Acute versus chronic infarctions.— Both acute (necrosis) and chronic (scar) myocardial infarctions show delayed enhancement after administration of gadopentetate dimeglumine and other contrast media that are distributed in the extracellular space (13). Therefore, when gadopentetate dimeglumine or other extracellular contrast media are used, acute and chronic infarctions cannot be distinguished on the basis of the presence of enhancement alone. Morphologic features such as wall thinning can be used to presume that an area of enhancement represents scar rather than acute necrosis.

Acute and chronic infarctions can also be differentiated by combining T2-weighted imaging with delayed gadolinium-enhanced imaging (36). T2-weighted images show a high-signal-intensity region larger than that on delayed gadolinium-enhanced images in cases of acute infarction; the difference between the two zones is presumed to be a peripheral region of reversible injury where there is myocardial edema but not infarction. Chronic infarction (scar) does not display hyperintensity on T2-weighted MR images.

Differentiation between acute and chronic myocardial infarction can also be accomplished by using both extracellular gadopentetate dimeglumine, which has low molecular weight, and another gadolinium-based contrast medium with larger molecular size (pseudo–blood pool medium). Low-molecular-weight gadolinium-based contrast media cause delayed enhancement of acute and chronic myocardial infarctions. Larger molecular weight contrast media cause enhancement.
of acute but not chronic myocardial infarction (37). In acute infarction, small intramyocardial blood vessels are destroyed so that blood pool contrast media escape the vascular space in the infarct but not in normal myocardium; hence, blood pool media have a larger distribution volume in the acute infarction. Neovascularization in the scar retains the intravascular distribution of the high-molecular-weight contrast medium.

Variation in infarct size over time.—Infarction size in experimental animals, as demarcated by enhancement of the ischemically damaged region on in vivo MR images, is largest in the first 2 days after coronary artery occlusion and decreases in size over the ensuing weeks to months according to a number of reports (38–40). Most of the studies in animals show a decrease in infarction size on gadolinium-enhanced T1-weighted spin-echo MR images acquired from the 1st days to several weeks after occlusion-reperfusion. On the other hand, other investigators (13), using sequential imaging in dogs, have found little or no decrease in infarction size from day 1 after ischemic injury to several weeks later. These studies have used the inversion-recovery gradient-echo sequence with nulling of signal of normal myocardium at 10–15 min after injection of gadolinium chelate. It is proposed that these discrepant observations may be related to the imaging sequence because, by maximizing contrast between normal and infarcted myocardium, images obtained with the inversion-recovery gradient-echo sequence may not depict the peripheral edematous zone.

Clinical Application in Ischemic Heart Disease

Delayed enhancement indicative of myocardial infarction is always subendocardial and extends to a variable degree through the wall, corresponding to the
STATE OF THE ART: Delayed Enhancement of Myocardium

Ordovas and Higgins

Figure 4: Graph shows differences in longitudinal relaxation time (ΔR1) ratio of myocardium to blood for myocardial ischemic injuries of increasing severity. The ratio is an estimate of distribution volume of the contrast medium (gadodiamide). The x-axis represents time after injection. (Adapted and reprinted, with permission, from reference 26.)

Figure 5: Diagram shows extracellular distribution of contrast medium in normal myocardium and reperfused infarcted myocardium. In normal tissue, gadopentetate dimeglumine and other contrast media (gray areas) distribute in the extracellular space and are excluded from the intracellular space. After infarction, cellular membrane integrity is disrupted, so media enters intracellular space, markedly increasing the distribution volume. RBC = red blood cell. (Reprinted, with permission, from reference 27.)

Figure 6: Diagrams show delayed-enhancement zones. ICZ = infarct core zone, PZ = peripheral zone. (a) Subendocardial myocardial infarction. (b) Transmural myocardial infarction with microvascular obstruction (MVO).

distribution area of a major coronary artery (Figs 8, 9). Multiple studies (41–53) in patients have shown that delayed-enhancement MR images can demonstrate the presence, location, and transmural extent of acute and chronic myocardial infarctions. An international multicenter study (54) reported a sensitivity of 99% for detection of acute infarction and 94% for detection of chronic infarction. Small infarctions, even those without Q waves, have been readily detected on delayed-enhancement MR images (55–57). Delayed-enhancement MR imaging depicts small infarcts that can be missed at ⁹⁹mTc sestamibi single photon emission computed tomography (SPECT) performed 7 days after percutaneous transluminal coronary angioplasty in patients with acute coronary syndrome (48). Delayed-enhancement MR imaging is more accurate than SPECT for detection of subendocardial infarction (48,56).

In patients with acute myocardial infarction, the infarction size, as defined by the extent of delayed gadolinium enhancement, correlated with clinical measures of infarction severity such as peak troponin level and left ventricular (LV) ejection fraction at late follow-up (49). In those patients reevaluated an average of 5 months after the acute event, the size of the area of delayed enhancement (infarction size) decreased almost 40% (49).

Schulz-Menger et al (58) sequentially evaluated delayed-enhancement MR images obtained from 1 hour to 180 days after induction of acute myocardial infarction by means of septal artery embolization for the treatment of hypertrophic cardiomyopathy. Delayed enhancement was observed 1 hour after embolization and persisted through the entire follow-up. The area of enhancement was significantly larger at days 7–14 than it was later. Other studies (45,49) have also indicated a substantial decrease in infarction mass from the acute to the chronic state.

Delayed-enhancement MR for predicting recovery of LV function.— A number of studies (41,44–46,48–50,59) have shown that delayed-enhancement MR imaging findings can be predictive of the potential for recovery of function...
in LV dysfunctional segments in chronic ischemic heart disease. Ramani et al (47) reported more than a decade ago that the presence or absence of delayed enhancement correlated closely with nonviability or viability in LV segments which were akinetic or dyskinetic at rest in patients with chronic ischemic heart disease.

Recovery of contraction in regions with dysfunction after revascularization has been related to the transmural extent of enhancement in patients with acute infarction, chronic ischemic dysfunction, and ischemic cardiomyopathy. Choi et al (41) found, in 24 patients with first infarction and successful early revascularization, that the transmural extent of enhancement 7 days after the acute event was predictive of recovery of wall thickening and ejection fraction at 8–12 weeks. The best predictor of global contraction as reflected in ejection fraction and mean wall thickening score was the extent of dysfunctional myocardium that had no delayed enhancement or delayed enhancement of less than 25% of wall thickness. Another group (53) found that late improvement in regional function was more closely predicted by a thickness of normal myocardium of greater than 5.5 mm in dysfunctional segments with delayed enhancement.

Kim et al (44) used transmural extent of delayed enhancement to predict recovery of regional function in dysfunctional segments in patients evaluated before and several months after surgical revascularization. A cutoff of 50% transmurality of delayed enhancement was a practical gauge of reasonable likelihood of recovery of regional function after revascularization—less than 50% transmurality predicted recovery in 53% of segments, while greater than 50% transmurality was associated with recovery in only 8% of segments. Less than 25% transmurality predicted residual viability in 82% of segments.

Predictions of viability compared with other tests.— Delayed-enhancement MR imaging and positron emission tomography (PET) for determination of myocardial viability after prior infarction have also been compared (60,61). The sensitivity and specificity of delayed-enhancement MR images for identification of LV segments flow metabolism defects on matched PET scans were 0.96 and 0.86, respectively. Infarct on delayed-enhancement MR images and infarct mass on PET scans correlated well: 11% of segments defined as viable on PET scans showed infarct on delayed-enhancement MR images, suggesting that the latter are more sensitive for detection of infarction because of the better spatial resolution of MR images. Fluorodeoxyglucose (FDG) uptake of more than 50% at PET and delayed gadolinium enhancement at MR with a peripheral nonenhancing rim thicker than 4.5 mm
Delayed-enhancement MR imaging alone for prediction of recovery of segmental function 3 months after revascularization (59). The advantage of dobutamine-stimulation cine MR was shown in segments with transmural delayed enhancement of 1%-75%. In patients with previous myocardial infarction in more than 50% of dysfunctional segments with transmural delayed enhancement of 25%-75% showed contractile reserve on dobutamine-stimulation echocardiography (62).

Delayed enhancement in the absence of history of myocardial infarction.—Delayed-enhancement MR imaging in 195 patients suspected of having coronary artery disease but with no history of myocardial infarction demonstrated delayed enhancement in nearly 23% of patients (63). During a 16-month follow-up period, delayed enhancement was the strongest predictor of mortality and major adverse cardiac events, as compared with clinical data, coronary sclerosis at angiography, or LV end-systolic volume index and ejection fraction. Even a small area of delayed enhancement (<2% of LV mass) was associated with a greater than seven-fold increase in risk for a major adverse cardiac event. Thus, delayed-enhancement MR imaging was proposed as a test to improve risk assessment in patients with possible coronary artery disease. It is conceivable that small “silent” infarct may be a precursor of a large infarct leading to major morbidity and mortality.

Delayed-enhancement MR imaging in 248 randomly recruited 70-year-old subjects demonstrated focal delayed enhancement in 24% of the subjects (64). In 49 of 60 patients, the site was subendocardial, indicating prior undetected myocardial infarction. The LV ejection fraction was lower and the mass was greater in those with unrecognized myocardial infarction than in the rest of the elderly subjects.

Prognostic implications of delayed enhancement with microvascular obstruction.—Most acute myocardial infarctions are associated with delayed enhancement in a subendocardial or transmural distribution. Acute infarction with microvascular obstruction (destruction) is recognized as midwall and/or epicardial enhancement surrounding a subendocardial region of low signal intensity (Figs 6, 10). This pattern is associated with greater infarct mass, lower ejection fraction, more adverse cardiac events early and late, and more severe late LV remodeling (43,65–69). Microvascular obstruction has a close direct relationship to infarction size and extent of transmularity (69).

Clinical implications of the peripheral zone.—Infarction size, as defined on the basis of voxels with signal intensity greater than 2 standard deviations above that of normal myocardium on delayed-enhancement MR images, was shown to be stronger predictor of inducible ventricular arrhythmia than is LV ejection fraction (70). In this initial report, central and peripheral zones of infarction were not discriminated.

More recently, sequential studies were performed in 144 patients after myocardial infarction to evaluate the prognostic role of peripheral zone findings (29). The peripheral zone was calculated by using the method described above. Patients with a larger peripheral zone had increased risk for mortality from all causes and cardiovascular mortality after a follow-up of 2.4 years. This association was independent of LV ejection fraction and LV volume. There was no correlation between the total size of the infarct or transmurality and the risk of death. The extent of the peripheral zone and the LV end-systolic volume index were the strongest predictors of mortality. The authors postulated that the association between extent of the peripheral zone and mortality is likely due to an increased substrate of viable myocyte “islands” in the peripheral zone, which could increase the risk for cardiac arrhythmia.

In agreement with the above notion, Schmidt and co-workers (71) have shown that extensive tissue heterogeneity correlates with increased ventricular irritability, as demonstrated with programmed electric stimulation. The presence of inducible ventricular arrhythmia is a marker for increased risk of lethal arrhythmia in patients with chronic myocardial infarction.
However, cellular space and accumulation of contrast medium with a nonischemic cause. A minority of patients in that study had delayed enhancement that is consistent with the subepicardium (37.5%).

The mechanism of delayed enhancement in the setting of myocarditis is not clear. A correlation between gadolinium enhancement ratio and cardiac dysfunction after a 3-year follow-up was demonstrated in one study (80).

Dilated cardiomyopathy.— Delayed-enhancement MR images can be useful for distinguishing between ischemic cardiomyopathy and idiopathic dilated cardiomyopathy. McCrohon et al (81) showed that 59% of patients with dilated cardiomyopathy and normal coronary arteries at conventional angiography showed no delayed enhancement, whereas 28% of patients had a midwall distribution of delayed enhancement that is consistent with a nonischemic cause. A minority of patients in that study had delayed enhancement with an ischemic distribution, which was thought to be related to a recanalized coronary obstruction. Recently, the extent of fibrosis depicted on delayed-enhancement MR images has been associated with increased risk of intraventricular systolic dyssynchrony in patients with nonischemic dilated cardiomyopathy (82).

Hypertrophic cardiomyopathy.— Delayed enhancement has been reported in 81% of patients with hypertrophic cardiomyopathy. The distribution is typically in the ventricular septum adjacent to the connection with the RV free wall (83). Areas of delayed enhancement had a midwall or subepicardial distribution but never involved the subendocardial region. Delayed enhancement also occurs in the region of most severe hypertrophy, such as the asymmetrically hypertrophied ventricular septum (Fig 12).

Delayed enhancement in patients with hypertrophic cardiomyopathy is most likely related to ischemic injury with myocardial collagen replacement (84,85). An alternative theory states that areas of myocardial disarray characteristically seen in hypertrophic cardiomyopathy at the junction of the ventricular septum and the RV free wall could also result in increased extracellular space and accumulation of contrast medium shown on delayed enhancement MR images (86). Ex vivo studies have demonstrated an association between fibrosis and sudden death in patients with hypertrophic cardiomyopathy.
Clinical studies have also demonstrated an association between the presence of myocardial fibrosis and the risk of developing ventricular arrhythmias. Adahag et al (90) showed that patients with hypertrophic cardiomyopathy and any degree of delayed enhancement have a seven-fold higher risk of nonsustained ventricular tachycardia (when they are being observed with 24-hour Holter monitoring) compared with patients without evidence of delayed enhancement. Surprisingly, the transmural extent of the delayed enhancement and the percentage of LV myocardium with delayed enhancement were not associated with ventricular arrhythmias. Satoh and co-workers (91) have demonstrated that the presence of delayed enhancement is not only correlated with prevalence of ventricular tachycardia on Holter monitoring, but is also associated with higher New York Heart Association functional class, impaired global LV function, conductance disturbance, abnormal Q waves, and giant T waves.

The authors of another report demonstrated that patients with hypertrophic cardiomyopathy and progressive LV dilatation, consistent with progressive disease, have more extensive delayed enhancement than do patients with stable disease (92). The same study also showed greater extent of enhancement in patients with two or more risk factors for sudden death.

Sarcoidosis.—Cardiac involvement has a reported prevalence of 7% in patients with pulmonary sarcoidosis (93). However, 20%–30% of postmortem examinations revealed cardiac involvement in sarcoidosis (94,93).

Delayed-enhancement MR images in patients with myocardial sarcoidosis have shown diffuse or focal enhancement in the middle of the myocardial wall or in the subepicardial region (Fig 13) (96,97). Delayed enhancement of the RV side of the septum is considered to be a characteristic feature (98). It has been reported that delayed enhancement in sarcoidosis involves predominantly basal segments of the LV, with the anteroseptal and anterolateral segments most frequently affected (99).

Matoh et al (100) identified delayed enhancement in only five (42%) of 12 patients with cardiac sarcoidosis, whereas Ichinose et al (97) reported this finding in 10 (91%) of 11 patients with cardiac sarcoidosis. Smedema and colleagues (101) demonstrated a correlation between extent of delayed enhancement and disease duration, ventricular dimensions and function, severity of mitral regurgitation, and presence of ventricular arrhythmias. Ichinose et al (97) also showed a significant correlation between global extent of myocardial enhancement with increased LV volume and decreased LV contractility.

Amyloidosis.—For the diagnosis of amyloidosis, delayed-enhancement MR imaging has a specificity of 94% and a sensitivity of 80%, with endomyocardial biopsy as the standard of reference (102). Global subendocardial delayed enhancement, the so-called amyloid late gadolinium-enhancement pattern, has been described in up to 80% of patients with amyloidosis (102–104) (Fig 14). Other distributions of delayed enhancement have been reported as patchy midwall, subendocardial, or subepicardial distribution. Most patients with global subendocardial delayed enhancement also showed papillary muscle involvement.

For acquisition of delayed-enhancement MR images, establishment of the optimal inversion time to null the signal of normal myocardium in patients with amyloidosis can be problematic (103). As proposed by Maceira and colleagues (103), multiple inversion times need to be used to determine the nulling point of normal myocardium, since areas with amyloid deposition typically demonstrate an inversion time shorter than that of the blood pool. In addition, contrast between normal myocardium and areas with amyloid deposition fades approximately 8 minutes after the administration of gadolinium chelate owing to altered contrast agent kinetics. Therefore, delayed-enhancement MR images in patients with possible cardiac amyloidosis must be acquired between 5 and 8 minutes after the administration of the contrast medium.

The mechanism for delayed enhancement in patients with amyloidosis is controversial. Theories include expansion of the extracellular space due to accumulation of abnormal interstitial protein or myocardial fibrosis due to perivascular amyloid deposition (105,106). The
former theory is supported by necropsy studies that have demonstrated typical global subendocardial amyloid deposits consistent with the most common distribution pattern seen on delayed-enhancement MR images (107). However, a small study (five patients) in which areas of delayed enhancement and histopathology findings were directly compared showed a significant correlation between the MR imaging abnormality and areas of fibrosis but no correlation with areas of myocardial amyloid deposition (106).

Regarding clinical and prognostic implications of delayed-enhancement MR imaging for amyloidosis, Perugini et al (104) showed that the presence of delayed enhancement has no correlation with clinical, functional, or histologic characteristics of the disease. In agreement, Ruberg et al (108) showed that delayed enhancement is not predictive of survival in a follow-up study of 21 patients with light-chain cardiac amyloidosis. However, that study demonstrated a correlation between delayed enhancement and B-type natriuretic peptide, a marker of heart failure severity.

**Rare Myocardial Diseases with Delayed Gadolinium Enhancement**

**Arrhythmogenic RV dysplasia/cardiomypathy.**—Delayed enhancement has been described in areas of fibrofatty myocardial changes in patients with arrhythmogenic RV dysplasia/cardio- myopathy (ARVD/C). Pfluger et al (109) reported delayed enhancement in seven (88%) of eight patients with ARVD/C; then enhancement predominantly involved the RV free wall but also affected the RV side of the ventricular septum. In most patients, it was associated with regional contraction abnormality. In addition, it has been shown that delayed enhancement has an excellent correlation with histopathologic diagnosis of fibrofatty infiltration in patients with ARVD/C (110). Tandri et al (110) showed that the presence of RV delayed enhancement is predictive of inducible ventricular tachycardia at programmed electric stimulation, which suggests a possible role of viability imaging in the prognostic assessment of patients with ARVD/C.

**Anderson-Fabry disease.**—Anderson-Fabry disease is an X-linked disorder of the sphingolipid metabolism, which should be considered in the differential diagnosis of symmetric hypertrophic cardiomyopathy. Delayed enhancement MR imaging demonstrates a typical and consistent pattern and site in patients with Anderson-Fabry disease, which is distinguishable from symmetric hypertrophy caused by hypertrophic cardiomyopathy. The characteristic pattern of delayed enhancement involves the mid-wall, sparing the subendocardial region, with a predilection for the inferolateral basal segments of the LV (111).

**Chagas disease.**—Cardiac involvement is very common in chronic Chagas disease, and lymphocytic infiltration of the myocardium is characteristic. Regions of myocardial fibrosis have been shown to enhance strongly on delayed-enhancement MR images, with a transmural, subepicardial, or midwall distribution (112,113). LV inferolateral basal segments and the apical region are the most commonly affected regions. Apical aneurysm of the LV with transmural delayed enhancement is characteristic of chronic Chagas disease. Delayed enhancement is seen more often in patients with advanced disease and worse clinical presentation than in patients with early cardiac involvement. In addition, all patients with ventricular tachycardia due to chronic Chagas disease showed delayed enhancement, suggesting a prognostic role for delayed-enhancement MR imaging in this disease.

**Churg-Strauss syndrome.**—A few case reports have demonstrated delayed enhancement of LV myocardium in Churg-Strauss syndrome. Pattern of delayed enhancement has varied including patchy distribution in subendocardial, midwall and subepicardial regions (114), predominant involvement of the ventricular septum (115) and diffuse sub-endocardial with papillary muscle involvement (116). Correlation with histopathology showed good match between the regional myocardial enhancement and the eosinophilic infiltrates (114).

**Lyme cardiomyopathy.**—Lyme cardiomyopathy affects between 1.5% and 10% of patients with Lyme disease and typically presents as atrioventricular block (117). Delayed enhancement has been described in a few case reports of patients with Lyme cardiomypathy. The abnormality on delayed-enhancement MR images involved the midwall region of the basal anteroseptal wall, which is the expected location of the atrioventricular node (118). Decrease in extent of delayed enhancement after 6 weeks of treatment has been shown to be accompanied by improvement of atrioventricular block,
which suggests a role for delayed-enhancement cardiac MR imaging for follow-up in these patients (118). Complete resolution of the delayed enhancement has been shown after clinical recovery (119).

**Endomyocardial fibrosis.**—Chronic fibrotic stage of endomyocardial fibrosis is characterized by the presence of scar in the subendocardium and chordae tendineae, resulting in congestive heart failure. In a few case reports (120–124), a typical appearance of biventricular delayed enhancement involving the subendocardial region with adjacent non-enhancing mural thrombus has been demonstrated. Rarely, there may be predominant RV involvement (Fig 15).

**Postoperative Congenital Heart Disease**

After surgical correction of congenital heart diseases, delayed enhancement is frequently seen at sites of prior surgical intervention (Fig 16). However, areas of delayed enhancement have also been demonstrated in myocardium remote from the surgical site.

After correction of tetralogy of Fallot, Oosterhof et al (125) identified delayed enhancement in the RV outflow tract (RVOT) in 17 (71%) of 24 patients. Most patients were adults and underwent a transannular patch type of repair. Some patients also had delayed enhancement in the base of the ventricular septum, corresponding to the site of the ventricular septal defect patch. Harris et al (126) also described delayed enhancement of the RVOT in 31 (91%) of 34 patients who underwent RVOT reconstruction and ventricular septal defect patch closure for correction of conotruncal abnormalities. Delayed enhancement involving the inferior RV insertion point and inferior or lateral LV walls has also been described (127).

The presence of delayed enhancement in RVOT after repair of tetralogy of Fallot has been associated with worse RV function, increased RV volumes and increased RVOT diameter. Interestingly, such an association was not seen in a
myocardial infarction show delayed enhancement of the myocardium indicates an expanded role for those techniques in ischemic heart disease. Technical developments in high-field-strength MR units may result in better visualization of microinfarcts and, therefore, add information on risk stratification in these patients. Thus, this technique may become essential in risk assessment and, perhaps, in selection of therapeutic options. Delayed enhancement in patients with ischemic heart disease without acute coronary syndrome may be a harbinger of subsequent large infarction and thus a predictor of adverse cardiovascular events.

Delayed-enhancement MR has been used experimentally to guide transcatheter delivery of genes and multipotential cells to the myocardium as a potential therapy for ischemic cardiomyopathy (130–132). Delayed gadolinium enhancement of the infarction site(s) provides a target for the transcatheter delivery of a therapeutic solution during LV catheterization. This approach seems attractive for more precise transcatheter delivery of angiogenesis growth factors and multipotential cells to the periphery of a chronic myocardial infarction.

Most research on and clinical applications of delayed-enhancement MR have until now been directed at the identification and quantification of bulk necrosis and/or fibrosis. Recently, a few reports on the use of delayed gadolinium enhancement to recognize and quantify diffuse myocardial fibrosis have been published (133–135). The technique for quantification of diffuse myocardial fibrosis involves the estimation of the distribution volume of gadolinium in the myocardium based on T1 relaxivity of myocardium relative to that of the blood pool over time. Since the extracellular volume of fibrosis is greater than that of normal myocardium, the distribution volume of diffusely fibrotic myocardium is greater than that of normal myocardium. Diffuse myocardial fibrosis has been identified with this technique in cases of heart failure and dilated cardiomyopathy and in adults with congenital heart disease and ventricular dysfunction. This application indicates a further expansion of the use of delayed-enhancement MR in the future for aid in characterizing the severity and predicting the outcome of diffuse myocardial diseases.

There has been increased interest in assessing delayed enhancement of the myocardium by using multidetector CT (136–140). It should be remembered that MR is substantially more sensitive to contrast differences than are x-ray-based techniques. Further technology developments in dual-energy CT have the potential capability for improving the contrast between normal and abnormal myocardium. It is questionable, however, whether this will ever reach the contrast sensitivity of the multiple MR sequences now available for myocardial tissue characterization. Moreover, special attention to radiation reduction methods will be crucial for development of a comprehensive CT protocol that includes coronary imaging and viability assessment.

**Disclosures of Potential Conflicts of Interest:**
K.G.O. No financial activities to disclose. C.B.H. No financial activities to disclose.

**References**


STATE OF THE ART: Delayed Enhancement of Myocardium


